Brief: Index Pharmaceuticals Enters Agreement With Parexel Biotech
30/03/2021 07:01
March 30 (Reuters) - InDex Pharmaceuticals Holding AB
INDEX.ST :
* INDEX PHARMACEUTICALS ENTERS AGREEMENT WITH PAREXEL
BIOTECH FOR
PHASE III CLINICAL STUDY OF COBITOLIMOD FOR ULCERATIVE COLITIS
* STUDY WILL EVALUATE EFFICACY AND SAFETY OF DRUG CANDIDATE
COBITOLIMOD FOR TREATMENT OF MODERATE TO SEVERE LEFT-SIDED
ULCERATIVE COLITIS.
Source text for Eikon: ID:nWkr13jYsK
Further company coverage: INDEX.ST
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))